



Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

139

***First Named Inventor or Application Identifier***

Gonzalez

EL 501 637 999 US

## APPLICATION ELEMENTS

**See MPEP chapter 600 concerning utility patent application contents.**

ADDRESS TO:

Assistant Commissioner for Patents

**Box Patent Application  
Washington, DC 20231**

1. ☒ Fee Transmittal Form  
*Submit an original, and a duplicate for fee processing)*
2. ☒ Specification [Total Pages 115]  
*(preferred arrangement set forth below)*
- Descriptive title of the Invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R&D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings *(if filed)*
  - Detailed Description of the Invention *(including drawings, if filed)*
  - Claim(s)
  - Abstract of the Disclosure
3. ☒ Drawing(s) (35 USC 113) [Total Sheets 19]
4. ☒ Oath or Declaration (Unexecuted) [Total Sheets 2]
- a. ☐ Newly executed (original or copy)
  - b. ☐ Copy from a prior application (37 CFR 1.63(d))  
*(for continuation/divisional with Box 17 completed)*  
**[Note Box 5 below]**
    - i. ☐ DELETION OF INVENTORS(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
- ☐ Incorporation By Reference *(useable if Box 4b is checked)*  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (*Appendix*)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission  
(*if applicable, all necessary*)
  - a. ☐ Computer Readable Copy
  - b. ☐ Paper Copy (identical to computer copy)
  - c. ☐ Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney  
(when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure ☐ Copies of IDS  
Statement (IDS)/PTO-1449 Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
14. ☐ Small Entity ☐ Statement filed in prior application,  
Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16. ☐ Other:

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:  
☐ Continuation    ☐ Divisional    ☐ Continuation-in-part (CIP) of prior application No: filed.

## 18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

20583||| (Insert Customer No.  
or Attach bar code label here)

or ☐ Correspondence address below

NAME \_\_\_\_\_

**Pennie & Edmonds LLP**

**ADDRESS**

1155 Avenue of the Americas
17 <sup>th</sup> Floor

CITY

New York

STATE

NY

ZIP CODE

10036-2711

COUNTRY

USA

TELEPHONE

**(212) 790-9090**

FAX

(212) 869-8864

**Burden Hour Statement:** This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



03/13/01

03-14-01

**PENNIE & EDMONDS LLP**

COUNSELLORS AT LAW  
1155 Avenue of the Americas  
New York, N.Y. 10036-2711  
(212) 790-9090

ATTORNEY DOCKET NO. 9882-015-999Date: March 13, 2001

Assistant Commissioner for Patents  
Box PATENT APPLICATION  
Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): Gonzalez et al.Executed on: March 13, 2001

Title of Invention: **ENGINEERED PROTEIN BINDING DOMAINS AND METHODS AND SYSTEMS FOR THEIR DESIGN AND USE**

**PATENT APPLICATION FEE VALUE**

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	133	-20	113	\$18.00 each	\$ 2,034.00
Independent	27	-3	26	\$80.00 each	\$ 2,080.00
Minimum Fee					\$ 710.00
Multiple Dependency Fee If Applicable (\$270.00)					\$ 0.00
<b>Total</b>					\$ 4,824.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern (a verified statement as to the applicant's status is attached)					\$ 0.00
<b>Total Filing Fee</b>					\$ 4,824.00

- ☐ **DO NOT PUBLISH.** I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).
- ☐ Priority of application no. filed on in is claimed under 35 U.S.C. § 119.
- ☐ The certified copy of the priority application has been filed in application no. filed
- ☐ Amend the specification by inserting before the first line the following sentence: This is a continuation-in-part of application no. filed .

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Adriane M. Antler  
PENNIE & EDMONDS LLP

Enclosure

32,605  
(Reg. No.)

Respectfully submitted,

Dwight H. Renfrew, Jr.  
PENNIE & EDMONDS LLP

38,594  
(Reg. No.)

**ENGINEERED PROTEIN BINDING DOMAINS  
AND METHODS AND SYSTEMS  
FOR THEIR DESIGN AND USE**

---

5

**TABLE OF CONTENTS**

1.	<u>FIELD OF THE INVENTION</u>	1
10	2. <u>BACKGROUND OF THE INVENTION</u>	1
	3. <u>SUMMARY OF THE INVENTION</u>	3
	4. <u>BRIEF DESCRIPTION OF THE FIGURES</u>	13
15	5. <u>DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT</u>	15
	5.1. <u>DOMAIN ENGINEERING/REDESIGN METHODS</u>	15
	5.1.1. <u>PREFERRED PRECURSOR DOMAINS</u>	15
	5.1.2. <u>GENERAL ENGINEERING/REDESIGN METHODS</u>	18
20	5.1.3. <u>PREFERRED TARGETS</u>	24
	5.1.4. <u>PREFERRED PRECURSORS</u>	27
	5.1.5. <u>SELECT CANDIDATE DOMAINS</u>	31
	5.1.6. <u>SCREENING CANDIDATE DOMAINS</u>	35
	5.2. <u>SCREENING METHODS</u>	44
25	5.2.1 <u>RECONSTITUTION METHODS</u>	45
	5.2.1.1 <u>PROTEIN-PAIR RECONSTITUTION METHODS</u>	45
	5.2.1.2 <u>LIBRARY-PAIR RECONSTITUTION METHODS</u>	47
	5.2.2 <u>DIRECT OBSERVATION OF BINDING</u>	51
	5.2.2.1 <u>AFFINITY CHROMATOGRAPHY</u>	52
30	5.2.2.2 <u>BIOSENSOR ANALYSIS</u>	54
	5.2.2.3 <u>PHYSICAL METHODS</u>	57
	5.2.2.3 <u>PHAGE DISPLAY</u>	58
	5.2.2.4 <u>RNA-PROTEIN FUSIONS</u>	59
	5.3. <u>DOMAIN SYNTHESIS</u>	61
35	5.3.1 <u>PREPARATION/MUTAGENESIS OF ENCODING DNA</u>	61
	5.3.2 <u>PROTEIN SYNTHESIS</u>	67

	<u>Page</u>
5.4. <u>SYSTEMS OF THE INVENTION</u> .....	68
5.5. <u>USES OF ENGINEERED BINDING PROTEINS</u> .....	70
5        5.5.1 <u>SINGLE DOMAINS</u> .....	70
5.5.1.1 <u>PDZ DOMAINS</u> .....	70
5.5.1.2 <u>TPR AND RELATED DOMAINS</u> .....	71
5.5.1.3 <u>PROLINE-SPECIFIC PEPTIDASES</u> .....	73
5.5.1.4 <u>CLASS II MHC PROTEINS</u> .....	74
10        5.5.2 <u>ALTERATION OF CELLULAR PROTEIN FUNCTIONS</u> .....	74
5.5.3 <u>ENZYMATIC BINDING SITES</u> .....	75
5.5.4 <u>PROTEIN LIBRARIES/SUBSTRATES</u> .....	76
5.5.5 <u>DIAGNOSTIC KITS</u> .....	79
5.6. <u>OTHER EMBODIMENTS/USES</u> .....	80
15        6. <u>EXAMPLES</u> .....	81
6.1 <u>THE PDZ DOMAIN</u> .....	81
6.2 <u>PDZ DOMAIN REDESIGN</u> .....	82
6.2.1 <u>RE-DESIGN TO BIND NATURAL TARGET</u> .....	83
20                6.2.2 <u>RE-DESIGN TO BIND A KINESIN</u> .....	84
6.2.3 <u>SELECTION OF SEQUENCES TO BE TESTED</u>	
<u>EXPERIMENTALLY</u> .....	86
6.3 <u>REDESIGNED PDZ DOMAIN ASSAYS</u> .....	87
6.3.1 <u>TWO-HYBRID ASSAYS</u> .....	89
25                6.3.2 <u>AFFINITY CHROMATOGRAPHY ASSAYS</u> .....	90
6.3.3 <u>MICRO-CALORIMETRIC ASSAY</u> .....	91
6.4. <u>EXPRESSION IN MAMMALIAN CELLS</u> .....	91

30

35